Last updated: February 20, 2026
Jordan's patent system, governed primarily by the Patents Law No. 24 of 2012, aligns with international standards but has specific criteria influencing patentability, enforceability, and claim scope for biopharmaceutical inventions.
Patentability Criteria for Biopharmaceuticals
Novelty
A biopharmaceutical invention must be new and not previously disclosed in any publication or public use anywhere globally. This includes disclosures in scientific journals, prior patent applications, or clinical trials conducted abroad. Jordan generally interprets novelty strictly, requiring the invention to differ in key structural or functional aspects from prior art.
Inventive Step
The invention should not be obvious to a person skilled in the field. For biopharmaceuticals, this criterion entails that the invention provides a surprising or unexpected technical contribution over existing knowledge. Jordan's patent office considers the technical problem solved and the inventive activity involved, especially for complex biological molecules or formulations.
Industrial Application
The invention must be capable of being produced or used in industry. For biopharmaceuticals, this includes the potential for large-scale manufacturing, clinical efficacy, and safety. Patent applications must demonstrate a practical utility aligned with Jordanian regulatory standards.
Patentable Subject Matter
Biological materials, gene sequences, or methods of treatment are patentable if they meet the above criteria. However, "discoveries" of naturally occurring substances or isolated endogenous DNA sequences without modification are typically not patentable. The invention should include an inventive step that transforms a discovery into a patentable invention.
Enforceability Considerations
Patent Rights
Jordanian patents provide exclusive rights for up to 20 years from the filing date. Enforceability depends on diligent maintenance, publication, and registration procedures are correctly followed. Patent owners can initiate legal action against infringers through the Jordanian courts, but enforcement effectiveness varies depending on the specifics of the case.
Challenges in Biopharmaceutical Enforcement
Patent disputes often involve complex biological material rights and process claims. Validity challenges may relate to prior art disclosures, sufficiency of disclosure, or claiming unpatentable subject matter. Jordanian courts consider legal precedents, international treaties, and the specifics of patent claims when resolving disputes.
Regulatory and Patent Linkage
Approval from the Jordan Food and Drug Administration (JFDA) is necessary for commercial sales but does not automatically influence patent enforceability. The patent office does not link patent status with drug approval, although infringement cases may involve regulatory data.
Scope of Claims
Claim Types
Biopharmaceutical patent claims often cover:
- Product Claims: Covering the specific molecular structure of a drug (e.g., monoclonal antibodies, recombinant proteins).
- Process Claims: Detailing methods of manufacturing, purification, or formulation.
- Use Claims: Covering specific therapeutic applications or indications.
- Formulation Claims: Covering drug delivery systems, excipients, or dosage forms.
Claim Strategy
Clarity and breadth are key. Jordanian practice favors narrow claims to ensure enforceability but allows broader claims if supported by the disclosure. Functional claiming is accepted if sufficiently supported, particularly for therapeutic uses, but overly broad claims risk invalidation during examination or litigation.
Limitations and Exclusions
Claims cannot encompass naturally occurring organisms or genetic material without a clear inventive step. Claims directed to diagnostic methods or surgical procedures may face restrictions based on Jordanian legal and ethical standards.
Policy and Practice Highlights
| Aspect |
Detail |
Implication for Biopharmaceutical Patents |
| Patent Term |
20 years from filing |
Standard global term, subject to maintenance fees |
| Patent Examination |
Based on novelty, inventive step, industrial application |
Similar to international norms; substantive examination required |
| Data Exclusivity |
Not explicitly provided, but market exclusivity is influenced by patent rights |
Patent provides primary market exclusivity |
| Patent Filing Requirements |
Detailed description, claims, abstract, prior art disclosure |
Must demonstrate inventive step and disclosure best practices |
| Handling of Biologics |
Patent protection is available for modified biological molecules, not for naturally occurring substances |
Modification or purification steps necessary for patentability |
Key Takeaways
- Jordanian patents require demonstrated novelty, an inventive step, and industrial utility, with specific challenges for naturally occurring biological material.
- Enforceability relies on clear, precise claims supported by detailed disclosures; legal disputes often hinge on claim scope and validity arguments.
- Broad claims are permissible provided they are adequately supported, though narrowly focused claims tend to enforce more straightforwardly.
- Patent protection lasts 20 years but requires diligent maintenance and compliance with procedural standards.
- Biopharmaceutical patent strategy should consider Jordan’s exclusion of naturally occurring substances and focus on innovative modifications or processes.
Frequently Asked Questions
1. Can naturally occurring genes be patented in Jordan?
Generally, no. Isolated endogenous genetic sequences without modification are considered discoveries rather than inventions and thus not patentable.
2. Are method of treatment patents available for biopharmaceuticals?
Yes. Jordan allows patents for new therapeutic methods if the claims meet novelty, inventiveness, and industrial applicability.
3. How does Jordan handle patent term extensions for biopharmaceuticals?
Extensions are not explicitly provided, but patent rights last 20 years from the filing date, with maintenance fees ensuring enforceability.
4. What are common grounds for patent invalidation in Jordan?
Lack of novelty, obviousness, insufficient disclosure, or claiming unpatentable subject matter.
5. Is data exclusivity recognized in Jordan?
No; patent rights provide market exclusivity, but distinct data exclusivity provisions are not outlined in Jordanian law.
References
[1] Jordan Patent Law No. 24 of 2012.
[2] World Intellectual Property Organization. (2020). Jordan: Patent Laws and Practice.
[3] International Drug Patent Legislation. (2021). Biopharmaceutical Patents and Practice.
